Exagen Inc. Q4 Loss of $0.20 Expected as EPS Estimates Fall 24%
Exagen Inc. is set to report Q4 December 2025 results on March 10 with analysts forecasting a $0.20 per share loss, unchanged year-over-year, after EPS estimates were cut 24.3% over the last 30 days. Revenue is projected at $16.3 million, a 19.4% increase from the year-ago quarter.
1. Q4 Report Expectations
Exagen Inc. will unveil its Q4 (December 2025) financials on March 10. Analysts predict a $0.20 per share loss, matching last year’s deficit, following a 24.3% cut in EPS estimates over the past month. Revenue is expected to reach $16.3 million, reflecting 19.4% year-over-year growth.
Related News
GOOGL
Google and Blackstone Form $5B AI Cloud JV for 500MW Capacity by 2027
GOOGL•
NVDL
GraniteShares 2x Daily Nvidia ETF Gains 172%, Tops $4 Billion AUM
NVDL•
EXR
Extra Space Storage Adds Retail and Tech Executives with 850-Unit Chain, Ex-Matterport CEO to Board
EXR•
JAGX
Jaguar Health Q1 Revenue Jumps 816% to $20.3M on $19M License Deal
JAGX•
TRU
TransUnion Adds YouTube Ad Measurement to MTA, Pilot with 15 Clients Validates ROI
TRU•
Sources
F